Pediatrik Nöroloji Hastalarında Metabolik Kemik Hastalıkları ve Osteoporoz
Özet
Nörolojik hastalıklar, özellikle hareketsizlik ve uzun süreli ilaç kullanımı nedeniyle çocuklarda kemik metabolizmasını bozarak osteoporoz ve kırık riskini önemli ölçüde artırmaktadır. Beslenme yetersizlikleri, D vitamini eksikliği ve antiepileptik veya steroid tedavileri, kemik mineral yoğunluğunun azalmasına yol açan temel sekonder faktörlerdir. Kemik sağlığının korunması, sadece iskelet bütünlüğü için değil, aynı zamanda sinir sisteminin temel işlevlerinin sürdürülebilirliği açısından da kritik öneme sahiptir. Tanı süreçlerinde düzenli takip, beslenme desteği ve tedavi yönetiminin optimize edilmesi, pediatrik nörolojik hastalarda ikincil kemik kaybının önlenmesinde hayati rol oynamaktadır.
Neurological disorders in children, exacerbated by immobility and chronic medication use, significantly impair bone metabolism, leading to increased risks of osteopenia, osteoporosis, and fractures. Nutritional deficiencies, lack of vitamin D, and long-term antiepileptic or steroid treatments are primary drivers of secondary bone loss in these patient populations. Maintaining skeletal health is essential not only for physical integrity but also for preserving neurological function, given the complex regulatory interplay between the nervous system and bone homeostasis. Proactive clinical monitoring, adequate nutritional support, and optimized treatment strategies are crucial for preventing secondary osteoporosis in children with chronic neurological conditions.
Referanslar
Swaiman, Kenneth F, Stephen Ashwal,et al. Swaiman's Pediatric Neurology: Principles and Practice. 2018. Internet resource.
Kelly RR, Sidles SJ, LaRue AC. Effects of Neurological Disorders on Bone Health. Front Psychol. 2020;11:612366.
Exeter D, Connell DA. Skeletal muscle: functional anatomy and pathophysiology. Semin Musculoskelet Radiol. 2010;14:97-105
Türkiye Endokrinoloji ve Metabolizma Derneği. Metabolik Kemik Hastalıkları. 2013 p 4-55
Houlihan CM, Stevenson RD. Bone density in cerebral palsy. Phys Med Rehabil Clin N Am 2009;20:493-508.
Hahn HB. Osteopenic Bone Diseases In: Koopman WJ. Arthritis and Allied Conditions. 13th Edition. Williams&Wilkins Company,1997, p:2203-2250.
Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008;122:398-417.
Ko A, Kong J, Samadov F, et al. Bone health in pediatric patients with neurological disorders. Ann Pediatr Endocrinol Metab. 2020 Mar;25(1):15-23.
Murthy L, Dreyer P, Suriyaarachchi P, et al. Association between High Levels of Parathyroid Hormone and Frailty: The Nepean Osteoporosis and Frailty (NOF) Study. J Frailty Aging. 2018;7(4):253-257.
Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000 Jan 21;100(2):197-207.
Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002 Nov 1;111(3):305-17.
Elefteriou F. Impact of the Autonomic Nervous System on the Skeleton. Physiol Rev. 2018 Jul 1;98(3):1083-1112.
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011 Jan;96(1):53-8.
Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6.
SoderpalmAC, MagnussonP, AhlanderAC, et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 2007;17:919-28.
RossAC, MansonJE, AbramsSA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
Zhang Y, Zheng YX, Zhu JM, Zhang JM, Zheng Z. Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis. J Zhejiang Univ Sci B. 2015;16(7):611-621.
Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010;112:1-10.
Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003;15:454-7.
Simm PJ, Bicknell-Royle J, Lawrie J, et al. The effect of the ketogenic diet on the developing skeleton. Epilepsy Res 2017;136:62-6.
Grover M, Bachrach LK. Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment. Curr Osteoporos Rep. 2017 Aug;15(4):271-282.
Bachrach LK. Diagnosis and treatment of pediatric osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2014 Dec;21(6):454-60.
Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020 Feb 24;18(1):20.
Alvarez Zaragoza C, Vasquez Garibay EM, García Contreras AA, et al. Bone mineral density and nutritional status in children with quadriplegic cerebral palsy. Arch Osteoporos. 2018 Mar 4;13(1):17
Nazif H, Shatla R, Elsayed R, et al. Bone mineral density and insulin-like growth factor-1 in children with spastic cerebral palsy. Childs Nerv Syst. 2017 Apr;33(4):625-630.
Trinh A, Wong P, Fahey MC, et al. Longitudinal changes in bone density in adolescents and young adults with cerebral palsy: A case for early intervention. Clin Endocrinol (Oxf). 2019 Oct;91(4):517-524.
Cheng SW, Ko CH, Lee CY. The effect of anticonvulsant use on bone mineral density in non-ambulatory children with cerebral palsy. Hong Kong Med J. 2016 Jun;22(3):242-8.
Bisson EJ, Finlayson ML, Ekuma O, Leslie WD, Marrie RA. Multiple sclerosis is associated with low bone mineral density and osteoporosis. Neurol Clin Pract. 2019 Oct;9(5):391-399.
Huang Z, Qi Y, Du S, Chen G, Yan W. BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci. 2015a;125(12):904-12
Huang Z, Qi Y, Du S, Chen G, Yan W. BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci. 2015b;125(12):904-12
Olsson A, Oturai AB, Søndergaard HB, Sellebjerg F, Oturai PS. Bone microarchitecture and bone mineral density in multiple sclerosis. Acta Neurol Scand. 2018 Mar;137(3):363-369.
Kasper LH, Shoemaker J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology. 2010 Jan 5;74 Suppl 1:S2-8.
Neumeyer AM, Cano Sokoloff N, McDonnell E, Macklin EA, McDougle CJ, Misra M. Bone microarchitecture in adolescent boys with autism spectrum disorder. Bone. 2017 Apr;97:139-146
Neumeyer AM, Gates A, Ferrone C, Lee H, Misra M. Bone density in peripubertal boys with autism spectrum disorders. J Autism Dev Disord. 2013 Jul;43(7):1623-9.
Neumeyer AM, O'Rourke JA, Massa A, et al. Brief report: bone fractures in children and adults with autism spectrum disorders. J Autism Dev Disord. 2015 Mar;45(3):881-7
Roke Y, van Harten PN, Buitelaar JK, et al. Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment. Eur J Endocrinol. 2012 Dec;167(6):855-63.
Amini A, Namvarpour Z, Namvarpour M, Raoofi A. Risperidone accelerates bone loss in rats with autistic-like deficits induced by maternal lipopolysaccharides exposure. Life Sci. 2020 Oct 1;258:118197.
Diemar SS, Sejling AS, Eiken P, Suetta C, Jørgensen NR, Andersen NB. Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study. Bone. 2019 Jun;123:67-75.
Zhang Y, Zheng YX, Zhu JM, Zhang JM, Zheng Z. Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis. J Zhejiang Univ Sci B. 2015 Jul;16(7):611-21.
Simm PJ, Seah S, Gorelik A, et al. Impaired bone and muscle development in young people treated with antiepileptic drugs. Epilepsia. 2017 Nov;58(11):1931-1938.
Shiek Ahmad B, Petty SJ, Gorelik A, et al. Bone loss with antiepileptic drug therapy: a twin and sibling study. Osteoporos Int. 2017 Sep;28(9):2591-2600.
Suljic EM, Mehicevic A, Mahmutbegovic N. Effect of Long-term Carbamazepine Therapy on Bone Health. Med Arch. 2018 Oct;72(4):262-266
Garip Ustaoglu S, Evis Z, Ilbay G, Boskey AL, Severcan F. Side-Effects of Convulsive Seizures and Anti-Seizure Therapy on Bone in a Rat Model of Epilepsy. Appl Spectrosc. 2018 May;72(5):689-705
Fan HC, Lee HS, Chang KP, et al. The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism. Int J Mol Sci. 2016 Aug 1;17(8):1242.
Veilleux LN, Rauch F. Muscle-Bone Interactions in Pediatric Bone Diseases. Curr Osteoporos Rep. 2017 Oct;15(5):425-432.
Joseph S, Wang C, Di Marco M,et al. Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network. Neuromuscul Disord. 2019 Jan;29(1):59-66.
Annexstad EJ, Bollerslev J, Westvik J,et al. The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy. Int J Pediatr Endocrinol. 2019;2019:4.
Nasomyont N, Keefe C, Tian C, et al. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporos Int. 2020 Dec;31(12):2449-2459.
Vai S, Bianchi ML, Moroni I, et al. Bone and Spinal Muscular Atrophy. Bone. 2015 Oct;79:116-20.
Shanmugarajan S, Swoboda KJ, Iannaccone ST, Ries WL, Maria BL, Reddy SV. Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol. 2007 Aug;22(8):967-73.
Homann CN, Ivanic G, Homann B, Purkart TU. Vitamin D and Hyperkinetic Movement Disorders: A Systematic Review. Tremor Other Hyperkinet Mov (N Y). 2020 Aug 25;10:32.
